First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

Table 2 Multiple logistic regression models for the validation and Silber and colleagues [1] studies

	MDACC study			Silber model
Variable	Odds ratio	95% CI	P	Odds ratio	95% CI	P
Radiotherapy + chemotherapy indicator^a	-			9.5	2.5–36.6	0.0011
Cycle 1 nadir ANC (× 10⁹/liter)	4.8	2.3–9.9	<0.0001	4.4	2.1–9.2	<0.0001
Cycle 1 hemoglobin decrease (g/dl)	1.8	1.0–3.3	0.0686	1.8	1.2–2.8	0.0074
n	143			95
Model χ²	21.2 (2 df)			30.3 (3 df)
Log-likelihood P	<0.0001			<0.0001
C-statistic	0.78			0.83
Hosmer–Lemeshow lack-of-fit P	0.1268			0.6140

CI, confidence interval; df, degrees of freedom. ^aNot applicable to MDACC study because patients were not treated with concurrent radiotherapy.

ISSN: 1465-542X